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The Scleroderma Clinical Trials Consortium (SCTC) represents many of the clinical researchers 
in the world who are interested in improving the efficiency of clinical trials in Systemic Sclerosis 
(SSc). The SCTC has established 10 working groups (WGs) to develop and validate better ways 
of measuring and recording multiple aspects of this heterogeneous disease.  These include groups 
working on arthritis, disease damage, disease activity, cardiac disease, juvenile SSc, the 
gastrointestinal tract, vascular component, calcinosis, scleroderma renal crisis, interstitial lung 
disease, and skin measurement.  Members of the SCTC may join any one or more of these 
groups. 
Some of the WGs have only recently started their work, some are nearing completion of their 
mandated tasks and others are in the midst of their projects.   
All these projects, which are described in this paper, will help to improve clinical trials and 
observational studies by improving or developing better, more sensitive ways of measuring 
various aspects of the disease. As Lord Kelvin stated,  “To measure is to know. If you cannot 
measure it you cannot improve it.”  The SCTC is dedicated to improving the lives of patients 





An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups. 
 The Scleroderma Clinical Trials Consortium(SCTC) represents the majority of 
researchers and clinicians in the world who have particular interest and expertise in the care of, 
and research in, systemic sclerosis (SSc, scleroderma). The mission of the SCTC is to advance 
knowledge about the treatment of SSc primarily by promoting efficient design, conduct, and 
reporting of results of clinical trials and observational studies.  To this end the SCTC has 
assembled an assortment ofworking groups (WGs) that are tasked to investigate various aspects 
of scleroderma.  In general, they are focused on better ways to measure various aspects of the 
disease.  These measures are essential for the conduct of good clinical trials and observational 
studies. 
In this report we will briefly summarize the projects of these WGs. 
1. Arthritis WG. PI: authors JG,PC and SJ. 
Musculoskeletal  disease in SSc leads to disability and poor quality of life1. Musculoskeletal 
disease including arthritis and tendinopathy has been observed in24% to 97% of SSc patients at 
some time during the course of their illness2. Synovitis, joint contracture, and tendon friction 
rubs (TFRs) are associated with early disease, disease severity, and with higher degrees of 
systemic inflammation3,4.   Joint synovitis and TFRs were shown to be independent predictive 
factors for disease progression in early SSc5. However, these manifestations are frequently 
overlooked in the context of clinical trials in part because outcome measures have not been 
developed for Musculoskeletal symptoms 6. This WG was formed in order to identify a core set 
of preliminary items considered as important for the study of arthritis and arthropathy in SSc.  
In order to explore the opinions of scleroderma experts regarding utility of potential outcome 
measures in SSc joint disease, we conducted a two-part Delphi exercise. We utilized web-based 
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technologies to conduct the Delphi exercise. In 2 rounds of electronic voting, experts from the 
SCTC email list were asked to rate various outcome measures with respect to their use in future 
clinical trials focused on arthritis in SSc. Individuals ranked each item 1-9 on a Likert scale with 
the intent to disregard any items with a mean score <3, keep items with a mean score >7 and 
reconsider items rated between 3 and 7. 
Fifty physicians from SCTC centers participated. They were provided with a list of 29 items to 
consider initially, which was increased to 31 items during the second round. Consensus was 
achieved after 2 rounds of voting.  The experts agreed that the following 7 items should be useful 
in an arthritis-focused SSc trial: 28 joint tenderness count, 28 joint swelling count, assessment of 
TFRs, assessment of contractures of small and large joints, C-reactive protein, Scleroderma 
Health Assessment Questionnaire-Disability Index, patient global visual analogue scale. No 
items on the list were ranked in the disregard category. 
The two round Delphi exercise identified 7 items considered by experts as well-suited for the 
study of arthritis in SSc, but there was considerable ambivalence regarding the performance of 
these potential outcome measures for SSc arthritis. The validation of these outcome measures for 
use in interventional studies of SSc-arthritis is called for and is the focus of this group moving 
forward. 
2. Disease Damage WG. PI: authors NF, MB, MN 
The Scleroderma (SSc) Clinical Trials Consortium Damage Index (SCTC-DI) Working Group 
was assembled in November 2013. The mandate of this working group of 24 members, including 
22 rheumatologists and 2 dermatologists from North and South America, Australia and Europe, 
was to develop the first disease Damage Index in SSc, an instrument to quantify organ damage in 
this disease. The SCTC-DI Working Group was aided by an Advisory Group of 7 non-
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rheumatology experts from the disciplines of cardiology, respiratory medicine, gastroenterology 
and nephrology, together with 3 patient partners. 
The first task of the SCTC-DI Working Group was to achieve a consensus definition of ‘damage’ 
in SSc. This was achieved through a two-round survey of the Working Group members, and 
consultation with the Advisory Group and patient partners. Items for potential inclusion were 
generated through a systematic review of the literature 7and items were added based on 
suggestions of the WG members, the Advisory Group and the patient partners. The final list of 
items was then presented in survey form to the members of the SCTC, who were asked to rate 
the appropriateness of each item, in terms of importance and feasibility, for inclusion in the 
SCTC-DI. In this manner, over 80 items were reduced to just over 50. Further item reduction and 
‘weighting’ was achieved through regression methods relating each item with the endpoints of 
quality of life (‘morbidity’) measured using SF-36 and mortality, in the Australian Scleroderma 
Cohort Study data set of over 1500 patients followed prospectively over a median follow-up of 4 
years. External validation of the SCTC-DI in the Canadian Scleroderma Research Group cohort 
has shown excellent performance characteristics against similar morbidity and mortality 
endpoints, and steady accrual of damage over time, indicating responsiveness in an observational 
cohort setting.  A manuscript reporting the derivation and initial validation of the SCTC-DI is 
currently being prepared for submission for peer review publication.  
Future projects include prospective validation of the SCTC-DI in the International Systemic 
Sclerosis Inception Cohort (INSYNC) of patients followed from disease onset, and assessment of 
discriminant validity in interventional studies. Future applications of the newly derived SCTC-DI 
include use as an outcome measure and enrichment tool for patient selection in clinical trials, a 
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tool to describe the course of the disease in observational studies, and an instrument to quantify 
disease burden for epidemiological studies and policy making.  
As activity and damage lie on the same continuum, the development of the SCTC-DI has laid the 
foundations for the development of an Activity Index using similar methodology. 
3. Disease Activity WG.  PI: authors LR, MB, MN 
The EUSTAR Activity Index (EScSG-AI) 8,9 is the only previously published SSc activity index.  
This activity index that was recently revised in 20179, has not yet been fully validated.  This 
remains an issue of great clinical significance as SSc continues to have the highest case-based 
mortality of any autoimmune connective tissue disease 10.  Thus, accurate identification of high 
disease activity is of utmost importance in order to apply targeted therapy to lower the risk of 
organ damage. 
The SCTC ActivityWG is a collaboration of international SSc experts working towards 
generating a weighted, multi-system index to identify and measure SSc disease activity.  A 
multidisciplinary advisory panel of non-rheumatology experts from various disciplines, including 
cardiology, respiratory medicine, gastroenterology and nephrology, and patient partners, has 
been assembled to provide advice and recommendations regarding aspects of disease activity 
relevant to their specific fields of expertise. 
As a first step in developing an activity index, the SCTC Activity WGdevelopeda consensus, 
conceptual definition of disease activity in SSc.  This conceptual definition of disease activity 
will then form the central construct of the planned SCTC Activity Index (SCTC-AI).  Careful 
attention will be paid to the Outcome Measures in Rheumatology (OMERACT) filters of truth, 
discrimination and feasibility11 in the development of the SCTC-AI.    
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Using a similar methodology to that employed in the development of SCTC Damage Index 
(SCTC-DI) (under peer review), development of items for the SCTC-AI will draw upon the 
expertise of the SCTC WG and systemic review of the literature.  Reduction and weighting of 
items will be performed using data from the Australian Scleroderma Cohort Study (ASCS). Data 
from the Canadian Scleroderma Research Group (CSRG) cohort study will be used for 
retrospective validation in an external cohort.  Prospective validation of the SCTC-AI will be 
performed in the International Systemic Sclerosis Inception Cohort (INSYNC), the largest 
prospective cohort of incident cases of SSc, in order to test the performance of the SCTC-AI in 
patients with recent-onset disease.  In all of these validation studies, the endpoints of interest will 
be health-related quality of life (HRQoL), physical function, organ damage (measured by the 
SCTC-DI), and mortality. 
By ensuring that the SCTC-AI has face value, measures what is intended, and readily 
discriminates between high and low disease activity states, it is hoped that the SCTC-AI will 
overcome the criticisms faced by other outcome measures and be the first fully validated SSc 
disease activity outcome measure. 
4. Cardiac WGPI: authors AV,LR, MB, MN 
The aim of the SCTC Cardiac WG is to develop a definition of primary cardiac involvement in 
SSc for use in clinical trials and in observational studies.  Currently, there is no consensus 
definition of SSc-cardiomyopathy and this is reflected in the highly variable reporting of SSc 
cardiac disease (SCD) and its prevalence.  SCD is highly heterogeneous and includes variable 
involvement of many cardiac structures including the myocardium, conduction system, 
pericardium and cardiac valves.  Early definitions of SCD have included congestive cardiac 
failure, arrhythmias requiring therapy and symptomatic Pericarditis 12,13. The prevalence of SCD 
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using these criteria was 15% in a cohort of patients with diffuse SSc and these patients, 
particularly those with symptomatic cardiomyopathy, had poor clinical outcomes13. 
Autopsy studies have demonstrated SCD in up to 80% of patients and whilst no individual 
finding is pathognomonic for SCD, features of microvascular damage, myocardial fibrosis and 
inflammation are considered characteristic of SSc heart disease 14,15.  A definition of SCD would 
ideally incorporate the underlying pathophysiological processes, however routine investigations 
such as electrocardiography, chest radiograph and transthoracic echocardiography are known to 
have a low sensitivity for the detection of SCD prior to the onset of clinically overt disease16. 
There is emerging evidence of a role for more sensitive diagnostic techniques such as tissue 
Doppler echocardiography(TDE),  and cardiac magnetic resonance imaging (CMR)17, and for 
biomarkers such as N-terminal pro B-type natriuretic peptide18, and high sensitivity cardiac 
troponin19,20. However, the clinical significance of abnormalities detected by newer investigation 
modalities remains uncertain.   
There are a significant number of other unresolved issues when considering SCD; namely, the 
effect of co-morbidities on the myocardium and attribution of cardiac disease to SSc, as well as 
appropriate screening algorithms and optimal treatment and follow-up of patients diagnosed with 
SCD.  The lack of an accepted, standardised definition of SCD impedes progress in all of these 
areas. 
The SCTC CardiacWG has recruited cardiologists from Europe, North America and Australia to 
assist in the development of a preliminaryworking definition of SCD.  The WG will be asked to 
consider the scope of cardiac disease that should be included in a definition of SCD.  Questions 
to be considered are should the definition of SCD be restricted to SSc affecting the myocardium 
only, and should SCD considered present only if patients are symptomatic?  A scoping literature 
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review of previously published definitions of SCD has been performed.  With these results and 
by drawing upon the expertise within the group, the Cardiac WG is aiming to develop a 
consensus, expert-opinion definition of SCD.  In parallel, the Cardiac WG is also developing a 
research agenda to pursue the role of novel echocardiography techniques and CMR in the 
diagnosis of SCD and establishing cohort studies to better describe the natural history of SSc 
cardiac disease.  
5. Juvenile scleroderma WG.  PI: Author IF 
Juvenile systemic scleroderma (jSSc) is a much rarer than the adult form.  The estimated 
prevalence is 3 per 1 million child based on the Administrative Claims Data from the United 
States (Beukelman and Foeldvari et al, in press JSRD). The only published cross sectional study  
regarding incidence from the United Kingdom and Irelandthat relied upon surveys of specialist, 
estimated a yearly incidence of 0.27 [0.10-0.50] per 1 million child21. 
Currently there is a proposed severity index published for jSSc22, which is a  modification of the 
Medsger severity index, however it is not yet validated.   In the evaluation of the juvenile 
severity index 22 in the juvenile scleroderma inception cohort population(www.juvenile-
scleroderma.com), the index appears to be unresponsive to improvement but it did correlate with 
the Modified Rodnan skin score( unpublished data Foeldvari et al). 
Several outcome measures exist for adult SSc patients including  the Valentini activity index9,  
the CRISS response index23, the Medsger severity index24 and the proposed SCTC damage 
index.  Unfortunately, none is validated in the pediatric population.  
As new therapeutics are investigated in adults with SSc, pediatric studies will be planned. It is 
crucial to define response index, activity index and remission in the pediatric population.  A 
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further important step for jSSc treatment studies is the decision of European Medical Agency on 
extrapolation of the data25,26, to license treatment faster for pediatric orphan diseases.   
The aim of the WG is to develop, adopt and validate outcome measures for jSSc. 
Three workshops took placeduring the annual meeting of the “Hamburg Symposium on Juvenile 
Scleroderma- Update on New Developments”, (www.juvenile-scleroderma.com) that were 
organised by Ivan Foeldvari, to develop a pediatric “CRIS” and other pediatricjSSc specific 
outcome measures.  In the last workshop a preliminary pediatric CRIS was proposed (manuscript 
in preparation).We are also in the process of validating the proposed pediatric and adult 
parameters in the juvenile scleroderma inception cohort (www.juvenile-scleroderma.com),and in 
the Childhood Arthritis and Rheumatology Research Alliance (CARRA) cohort.  
We hope that we will have a validated instrument, regarding definition of activity, response, 
remission and damage, which can be applied in Phase II and III studiestesting new therapy for 
jSSc. The indices will help clinicians in the day to day practice too. 
6. Gastrointestinal Tract WG PI: authors TF, ZM, DK 
Gastrointestinal (GI) tract symptoms are very common in SSc.  The etiology of these symptoms 
is thought to be similar to other organ system pathophysiology with interrelated progressive 
immune dysregulation, vasculopathy, and fibrosis occurring throughout the GI tract.  The study 
of GI symptoms in SSc must capture not only the severity of involvement, but also response of 
those symptoms to intervention.  The ideal patient reported outcome measure should be able to 
provide information to guide the treating physician and inform clinical trial design while also 
minimizing the burden on the patient.  TheSCTC-GI-WG acknowledges the unmet need of a 
longitudinal assessment of response to therapy in SSc-associated GI tract involvement 27. Patient 
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reported outcomes measurement system (PROMIS) questionnaires were developed to 
characterize GI symptoms from the esophagus to the anorectum. The GI-WG focused on 
assessing psychometric properties of various GI-specific patient reported outcome measures in 5 
conditions—gastroesophageal reflux disease, gastroparesis, small intestinal bowel bacterial 
overgrowth, constipation, and fecal incontinence. Our WG comprises six international 
scleroderma centers from the United States and one each from Italy, Belgium and Australia. All 
data is entered at baseline and in follow-up into a database which was developed and is 
maintained at the University of Michigan. 
We recently assessed the reliability, validity, and sensitivity to change of 3 PROs- the NIH 
PROMIS-GI Symptoms scale, the Scleroderma Clinical Trials Consortium University of 
California Los Angeles Gastrointestinal Tract (SCTC UCLA GIT 2.0), and the Quality of life in 
Reflux and Dyspepsia 28, in 116 participants with SSc and active GERD with an average age of 
53.8 years and mean disease duration of 12.0 years. The UCLA GIT 2.0 Reflux scale and 
PROMIS Reflux scale had a significant correlation at baseline (0.61, p=<0.0001), and both 
instruments correlated with the QOLRAD domains (-0.56 to -0.71). Both UCLA GIT 2.0 and 
PROMIS Reflux scales were sensitive to change over time in patients who improved over a 
period of 4 weeks after an intervention. 
The SCTC GI WG is now actively recruiting patients for the other SScGI symptom domains. 
The next anticipated step is to better clarify the etiology of bloating and distention in an 
international cohort. Patient reported outcomes instruments that are applied to this cohort after a 
single intervention for GI symptoms can help inform clinical practice and trial design. 
7. Vascular WG.  PI: authors JP, RD  
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The aims of the SCTC Vascular WG (VWG) are to develop/improve outcome measures for SSc 
vascular manifestations. Challenges in establishing treatment efficacy in clinical trials of 
Raynaud’s phenomenon (RP) led the nascent SCTC-VWG to appraise existing methods for 
assessing SSc-RP. The Raynaud’s Condition Score (RCS) is the preferred outcome measure for 
SSc-RP and is included in the provisional core set of outcome measures for SSc clinical trials 29. 
The RCS diary collects information on the frequency, duration and severity/impact of RP in 
SSc30. It is a clinician-derived patient-reported outcome [PRO] instrument, but there was no 
patient involvement in its development31. Therefore, studies have identified poor agreement 
between the RCS diary and objective methods for assessing digital microvascular function 32,33. 
Concerns have also been raised about the magnitude of the placebo effect in clinical trials 
incorporating the RCS diary 34. 
The SCTC-VWG undertook a survey of the attitudes of SSc experts towards the RCS diary. The 
SURPASS (Subjective Raynaud’s phenomenon Assessment in Systemic Sclerosis) survey 
identified several concerns about the 2-week RCS diary including the respondent burden and an 
inability to control for factors that might influence the reporting of RP symptoms 35.  
To this end, SCTC funding was obtained to devise a conceptual framework for a novel patient-
derived PRO instrument for SSc-RP, supported by a steering committee comprising SSc patients, 
SSc experts and qualitative researchers. 
Preliminary work included a comprehensive literature review that has highlighted the significant 
burden associated with SSc-RP not captured by the RCS diary36. A multicenter qualitative 
research study designed to examine the patient experience of SSc-RP from a broad ethnic, 
geographic and cultural population of SSc patients has supported and expanded these findings 37. 
A purposive sampling framework ensured the enrollment of a diverse but representative group of 
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40 patients with SSc. We identified important experiences of SSc-RP not captured by the RCS 
diary including emotional distress, body image dissatisfaction, impaired social participation and 
relevant physical symptoms such as feeling “cold” 37. Our findings have challenged the 
prevailing paradigm of SSc-RP being only an episodic phenomenon with physical symptoms 
such as pain, numbness and loss of hand function reported in a more sustained manner and 
reflecting persistent digital ischemia in SSc37. The considerable efforts taken by patients to avoid 
or ameliorate SSc-RP attacks were a major theme of the focus groups 37. In parallel work, SSc 
patients attending UK and US sites undertook2-week RCS diary collection and then completed a 
qualitative survey examining patient attitudes towards the instrument 38. The findings confirmed 
our suspicions that the RCS diary underestimates the true burden of RP symptoms and provides 
insight as to why the RCS diary has not performed as well as hoped in clinical trials whose 
primary endpoint is the frequency of SSc-RP attacks 38-40.  
Work within the SCTC-VWG is currently underway on item-generation for a novel PRO 
instrument for SSc-RP, grounded in the patient experience of SSc-RP identified in our 
preliminary work. 
8. Calcinosis WG PI: author LC, AV 
Calcinosis cutis, the deposition of calcium in the skin and subcutaneous tissues, is a common and 
potentially debilitating issue affecting approximately one quarter of SSc patients41,42. To date, 
there are no effective therapies for this complication and there is a lack of validated outcome 
measures to use in clinical trials43. The SCTC Calcinosis-WG is an international collaborative 
effort to create new trial outcome measures and better understand the course and consequences 
of this complication.  
Studies have shown an association between calcinosis and vascular manifestations of 
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SScincluding digital ulcers (DUs, 44-46 and acro-osteolysis47, suggesting a role for ischemia in the 
pathogenesis of calcinosis. In addition, microtrauma has been implicated in the pathogenesis of 
calcinosis, and a prior single-center study found that the thumbs were most commonly affected, 
supporting this hypothesis48. 
Our group performed a retrospective analysis involving 5218 patients with SSc from 9 cohorts 
within the US, Australia, Canada, United Kingdom, Italy, and Mexico. In multivariate analysis, 
the strongest associations with calcinosis were DUs and osteoporosis42. 
Our group has developed a novel radiographic scoring system to assess the severity of calcinosis 
affecting the hands that accounts for area coverage, density, and anatomic location. This scoring 
system was found to have excellent intra- and inter-rater reliability with intra-class correlation 
coefficients (ICC) of .93 (.89-.97) and .89 (.86-.92), respectively49. Similarly, we have developed 
a patient reported outcome measure specific to calcinosis (the Mawdsley Calcinosis 
Questionnaire, 50. 
We have established a prospective multi-center cohort of SSc patients with and without 
calcinosis to better define the natural history, confirm clinical associations, and further validate 
these novel outcome measures. Data is being collected from 15 centers, 8 of whom are also 
participating in a sub-study to validate the radiographic scoring system.  
We are collecting patient questionnaires at baseline and 1-year, including the Cochin Hand 
Functional Scale, Scleroderma Health Assessment Questionnaire, patient global assessment of 
calcinosis using a visual analog scale (VAS, 0-10), and the novel Mawdsley calcinosis 
questionnaire. In addition, physician global assessment of calcinosisVAS is being collected at 
baseline and 1-year, and a 5-point Likert scale at the 1-year visit for both patients and physicians 
to rate change in calcinosis.  
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Information on 556 patients has been entered into the central database from which 134 have 
completed 1-year follow-up and 60 are participating in the radiographic sub-study. Enrollment is 
expected to be completed in March 2018. We plan to compare patients with and without 
calcinosis with respect to demographic characteristics, clinical features, and autoantibodies, and 
to specifically assess the association between calcinosis and DU or osteoporosis, adjusting for 
other relevant variables. We will also determine the mean rate of change of calcinosis for the 
subset of patients who have baseline and 1-year hand radiographs49. We hope to identify a 
subgroup of patients with rapid calcinosis progression and to determine risk factors for this 
severe phenotype.  
9. Scleroderma Renal Crisis WG.  PI: authors MH,CD 
Scleroderma Renal Crisis (SRC) is characterized by acute, malignant hypertension and renal 
dysfunction. It is a rare complication of SSc, affecting approximately 5% of subjects. The clinical 
spectrum of SRC is broad, ranging from new onset accelerated arterial hypertension and rapidly 
progressive oliguric renal failure, to more modest elevations in blood pressure and renal 
dysfunction, and at times normotensive presentations. To date, two sets of criteria for SRC have 
been proposed and partially validated51,52. We wish to build on these preliminary efforts to develop 
classification criteria for SRC and improve systematic research in this condition. 
The SCTC SRC-WG that consistsof international experts from rheumatology, nephrology and 
pathology was created in November 2015. A scoping review to generate evidence-based items to 
define SRC was performed during 2016, presented to the SCTC SRC WG in Washington, DC, in 
November 2016, and published in February 2017 53. We identified 415 papers that met inclusion 
criteria. Forty original definitions of SRC were identified from 36 studies, 9 reviews and 2 
editorials. There was significant heterogeneity in definitions. In May-October 2017, we conducted 
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a 3-round online Delphi exercise to develop initial consensus on a core set of items to define SRC. 
A survey using the items identified by the scoping review was developed. An international, 
multidisciplinary panel of experts from the SCTC, European Scleroderma Trials and Research 
Group (EUSTAR), the Canadian Scleroderma Research Group (CSRG), and the Australian 
Scleroderma Interest Group (ASIG) were invited to participate. A Delphi exercise was performed 
in 3 rounds. In Round 1, participants were asked to identify omissions and clarify ambiguities. The 
survey was modified accordingly. In Round 2, participants were asked to rate the scientific validity 
and feasibility of the items using Likert-type scales ranging from 1-9 (1= very invalid/unfeasible, 
9 = very valid/feasible), and to provide comments. In Round 3, participants reviewed the results 
and were asked to provide final ratings. Consensus was defined as items rated highly valid and 
feasible (both median scores ≥7) in Round 3, and for which there was no disagreement, calculated 
using the RAND/UCLA Appropriateness Method formula54. Ninety-nine experts from 17 
countries participated in the Delphi exercise. Of the 31 items in the survey, consensus was achieved 
on items pertaining to hypertension, kidney dysfunction, proteinuria and hemolysis. Consensus 
was not achieved on items pertaining to hematuria, thrombocytopenia, encephalopathy, 
retinopathy, hyper-reninemia, cardiac dysfunction and histopathology. 
In November 2017, a nominal group discussion was held in San Diego, CA, to achieve final 
consensus on the core set. Final consensus was achieved on items for blood pressure, acute kidney 
injury, microangiopathic hemolytic anemia and thrombocytopenia, target organ dysfunction 
(cardiac dysfunction, retinopathy and encephalopathy) and histopathology.  
Two additional components of this research project are now in the planning phases. First, modeled 
on the International Scleroderma Renal Crisis Survey (ISRCS,52, ISRCS II will be developed and 
launched to collect a new inception SRC cohort to validate the consensus criteria using data-driven 
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methods. Second, a forced choice study using multi-criteria decision analysis methods55, will be 
performed with the experts who participated in the nominal group discussion to assign weights to 
the items in the criteria.  
This project will generate the first validated classification criteria for SRC. These criteria are 
expected to become the international standard and will be used in future randomized trials and 
epidemiologic research of SSc. 
10. Skin WG.  PI: authors JG, PM, DK 
Skin involvement in SSc is the most pathognomonic feature and an important manifestation of 
disease and a marker of severity 56,57 , which makes its assessment a key outcome in clinical 
research in SSc. Skin involvement is routinely quantified using the 17-site modified Rodnan skin 
score (mRSS) which assesses global dermal thickness through clinical palpation of 17 body areas 
scored using a 4-point ordinal scale. The mRSS has high feasibility, validity (face, content, 
construct, and criterion), reliability, and sensitivity to change58. The goal of this SCTC WG is to 
explore ways to improve the assessment of skin disease in SSc. 
Although mRSS has excellent intra-rater and inter-rater reliabilities59,60 individual examiners 
approach the mRSS in different ways in clinical practice. Commonly-used techniques for a given 
area of the body include choosing a maximum score, a representative area, or a global average. If 
the examiner is consistent with his or her approach to scoring each time, the mRSS will be valid 
in the course of a trial. However, it is possible that maximizing the score may lead to decreased 
sensitivity to change of the mRSS. This WG plans to explore this controversy.  
It has been observed that certain areas of the body are more sensitive to change than others. Kaldas, 
et al showed that hands, forearms and chest were more sensitive to change compared with other 
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body sites in two human recombinant relaxin and oral bovine collagen clinical trials61. Fernandez, 
et al showed a lower propensity for change of the fingers over the course of 3 single-center trials62. 
These observations lead to the question of whether decreasing the number of body sites by 
exclusion of relatively static areas would further increase the sensitivity to change over time or 
reliability of the total MRSS. Our goal is to look at these questions in the context of studies that 
show more significant change as well as over a longer duration.  
Further goals of this group will include investigation of complementary methods of assessing skin 
disease that can studied as secondary outcomes in clinical trials. Ideas include percentage change 
mRSS, percentage of body involvement, and possibly use of skin biopsies, ultrasound, or 
durometry depending on investigator interest. Importantly, the WG seeks to align its agenda with 
the SCTC’s efforts to standardize skin scoring and advance the science of clinical trials in SSc. 
11. Lung DiseaseWG.  PI: authors EB, SN 
Interstitial lung disease (ILD) is the primary cause of death in SSc63. Although there have been 
many trials for the treatment of SSc-ILD, inclusion criteria have varied widely across studies and 
it remains unclear which patients to enroll to maximize the likelihood of achieving the 
predefined primary endpoints.  
The aim of this WG is to harmonize inclusion criteria for clinical trials of SSc-ILD. We have 
reviewed the inclusion and exclusion criteria for 9 completed and ongoing SSc-ILD clinical trials 
since the year 200064-74.While age at time of enrollment and SSc classification criteria were 
fairly consistent across studies, there was considerable variability with respect to disease 
duration, pulmonary function test (PFT) cut points, high resolution computed tomography of the 
chest (HRCT) characteristics, and acceptable background therapies. While some inclusion and 
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exclusion criteria will need to be specific to the particular drug being investigated, developing 
“optimal inclusion criteria” may ultimately help improve outcomes of SSc-ILD clinical trials.  
At the inaugural meeting of the SCTC Lung Disease WG in  2017, an initial research agenda was 
defined as determining how best to define progression of SSc-ILD and whether  SSc-ILD 
progresses in patients who have had SSc for ≥ 7 years.  We will perform a nominal group 
technique and Delphi exercise to develop consensus among SSc experts. We will then apply the 
core set of inclusion and exclusion criteria to clinical trial data and observational cohort data to 
validate their performance. Using well-established SSc cohorts throughout the world and 
applying the definition of progressive SSc-ILD that we develop, we will subsequently determine 
whether patients with ≥ 7 years of disease have progression of their ILD. 
Conclusions 
The SCTC WGsare one aspect of an organization tasked with improving the efficacy of clinical 
trials.  This interim report summarizes the work of the SCTC WGs to date.  
The groupshave benefited greatly from the input and effort of the SCTC members who have 
attended meetings over many years.  Members generously contributed their time, effort and 
wide-ranging expertise on subjects as diverse as the disease that we are studying.  Members’ 
involvement has ensured that the WGs reports will reflect a wide range of perspectives and 
skills.Leaders of the groups are grateful for the tireless input of all those who have been involved 
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